betrixaban (Bevyxxa)

From Aaushi
Jump to navigation Jump to search

Indications

Dosage

  • 160 mg PO once, then 80 mg/day for 35-42 days

Pharmacokinetics

  • maximum concentration 3-4 hours after oral dose
  • 1/2life of 19-25 hours; 20 hrs[4]

Adverse effects

-increased risk of hemorrhage

Mechanism of action

More general terms

References

  1. Green D Prevention of Venous Thromboembolism in Hospitalized Medical Patients. NEJM Journal Watch. June 2, 2016 Massachusetts Medical Society (subscription needed) http://www.jwatch.org
    Cohen AT, Harrington RA, Goldhaber SZ et al. Extended thromboprophylaxis with betrixaban in acutely ill medical patients. N Engl J Med 2016 May 27 PMID: https://www.ncbi.nlm.nih.gov/pubmed/27232649
  2. Gibson CM, Chi G, Halaby R et al Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients: An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban). Circulation. 2017 Feb 14;135(7):648-655. Epub 2016 Nov 14. PMID: https://www.ncbi.nlm.nih.gov/pubmed/27881569
  3. Windle ML. FDA New Drug and Biologic Approvals -- 2017 Year-in-Review Medscape - Jan 11, 2018. https://reference.medscape.com/viewarticle/890871
    U.S. Food and Drug Administration. Novel Drug Approvals for 2017. https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm537040.htm
  4. 4.0 4.1 Medical Knowledge Self Assessment Program (MKSAP) 18, American College of Physicians, Philadelphia 2018
  5. HIGHLIGHTS OF PRESCRIBING INFORMATION BEVYXXA <TM> (betrixaban) capsules, for oral use. https://www.bevyxxa.com/wp-content/uploads/2017/11/bevyxxa-betrixaban-capsules-prescribing-information-pdf.pdf

Database